Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALZ 002

Next Previous
Drug Profile

ALZ 002

Alternative Names: AJ-201; ALZ002; ALZ002 DS; Asc-JM-17; ASC-JM17; JM17

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AndroScience Corporation
  • Developer AnnJi Pharmaceutical
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Androgen receptor degradation enhancers; NF-E2-related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinocerebellar degeneration; Huntington's disease; X-linked bulbo-spinal atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II X-linked bulbo-spinal atrophy
  • No development reported Huntington's disease; Muscular dystrophies; Spinocerebellar degeneration

Most Recent Events

  • 22 May 2025 Efficacy, adverse event, pharmacodynamics and pharmacokinetics data from a phase Ib/IIa trial in X-linked bulbo-spinal atrophy released by AnnJi Pharmaceutical
  • 03 Mar 2025 Avenue Therapeutics receives a purported termination letter from AnnJi Pharmaceutical to terminate license agreement for AJ 201 and are currently embroiled in a dispute with them regarding such attempted termination
  • 28 Jun 2024 No recent reports of development identified for preclinical development in Huntington's-disease in Taiwan (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top